Journals / Journal of Clinical Research in Pediatric Endocrinology / 2019 / Cilt: 11 - Sayı: 2

Efficiency of Single Dose of Tolvaptan Treatment During the Triphasic Episode After Surgery for Craniopharyngioma

Pages
202–206
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The patient responded rapidly to a single dose of tolvaptan, with no adverse effect, which resulted in successful control of her SIADH.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Inappropriate antidiuretic hormone syndrome (SIADH) may develop after intracranial surgery.
📊
Key Findings & Data:We present a 13 year-old female with SIADH of triphasic episode who was transferred to our clinic after surgery for craniopharyngioma.
💡
Conclusion & Impact:The patient responded rapidly to a single dose of tolvaptan, with no adverse effect, which resulted in successful control of her SIADH.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Inappropriate antidiuretic hormone syndrome (SIADH) may develop after intracranial surgery. SIADH in the pediatric age group is usually encountered in patients with an intracranial mass both before and after surgery. Fluid restriction is the standard therapy in SIADH. However, a resistant, hyponatremic pattern may be encountered in some cases. Vaptans have been recently introduced for treatment of hyponatremia due to SIADH. There is inadequate data concerning tolvaptan treatment in pediatric patients. We present a 13 year-old female with SIADH of triphasic episode who was transferred to our clinic after surgery for craniopharyngioma. Resistant hyponatremia did not resolve despite fluid restriction and hypertonic saline support. The patient responded rapidly to a single dose of tolvaptan, with no adverse effect, which resulted in successful control of her SIADH.

🔖

Cite This Article

GÜRBÜZ, F., TAŞTAN, M., TURAN, İ., YÜKSEL, B. (2019). Efficiency of Single Dose of Tolvaptan Treatment During the Triphasic Episode After Surgery for Craniopharyngioma. Journal of Clinical Research in Pediatric Endocrinology, Cilt: 11 - Sayı: 2, 202–206. https://ajindex.com/articles/197638

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Tzoulis P, Carr H, Bagkeris E, Bouloux PM. Improving care and outcomes of inpatients with syndrome of inappropriate antidiuresis (SIAD): a prospective intervention study of intensive endocrine input vs. routine care. Endocrine 2017
  2. Epub 2016 Nov 12 2. Zieg J. Evaluation and management of hyponatraemia in children. Acta Paediatr 2014
  3. Epub 2014 Jul 1 3. Willemsen RH, Delgado-Carballar V, Elleri D, Thankamony A, Burke GA, Nicholson JC, Dunger DB. Tolvaptan use during hyperhydration in paediatric intracranial lymphoma with SIADH. Endocrinol Diabetes Metab Case Rep 2016:2016. Epub 2016 Nov 1 4. Verbalis JG, Grossman A, Höybye C, Runkle I. Review and analysis of differing regulatory indications and expert panel guidelines for the treatment of hyponatremia. Curr Med Res Opin 2014
  4. Epub 2014 May 14 5. Tuli G, Tessaris D, Einaudi S, De Sanctis L, Matarazzo P. Tolvaptan Treatment in Children with Chronic Hyponatremia due to Inappropriate Antidiuretic Hormone Secretion: A Report of Three Cases. J Clin Res Pediatr Endocrinol 2017
  5. Epub 2017 May 17 6. Marx-Berger D, Milford DV, Bandhakavi M, Van’t Hoff W, Kleta R, Dattani M, Bockenhauer D. Tolvaptan is successful in treating inappropriate antidiuretic hormone secretion in infants. Acta Paediatr 2016
  6. Epub 2016 Apr 14 7. Moritz ML, Ayus JC. Prevention of hospital-acquired hyponatremia: a case for using isotonic saline. Pediatrics 2003
  7. Aditya S, Rattan A. Vaptans: A new option in the management of hyponatremia. Int J Appl Basic Med Res 2012
  8. Peri A. Clinical review: the use of vaptans in clinical endocrinology. J Clin Endocrinol Metab 2013
  9. Epub 2013 Feb 11 10. Peters S, Kuhn R, Gardner B, Bernard P. Use of conivaptan for refractory syndrome of inappropriate secretion of antidiuretic hormone in a pediatric patient. Pediatr Emerg Care 2013
  10. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008
  11. Muto S, Kawano H, Higashihara E, Narita I, Ubara Y, Matsuzaki T, Ouyang J, Torres VE, Horie S. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol 2015
  12. Epub 2015 Feb 7 13. Kraayvanger L, Latza J, Vockelmann C, Berlit P, Weber R. Tolvaptan treatment of severe stroke-like symptoms and bilateral subcortical diffusion res